Abstract
On the basis of currently available information, the cumulative incidence of second malignant neoplasm (SMN) for neuroblastoma patients is approximately 2% at 20 years from the initial diagnosis. The most commonly observed SMNs include thyroid carcinomas, osteogenic and soft tissue sarcomas, breast and colon carcinomas, acute myeloid and lymphoid leukemias, Hodgkin's and non-Hodgkin's lymphomas, and brain tumors. Female survivors of neuroblastoma seem to be at higher risk of developing an SMN than males. Other predisposing factors include young age at the time of diagnosis of the first cancer, radiotherapy associated with chemotherapy, high-doses of alkylating agents and administration of topo-isomerase II inhibitors, as well as high cumulative doses and protracted schedules of epipodophyllotoxins. Longer and more targeted surveillance should be recommended including specific cancer screening at younger ages compared to the general population. Risk adapted and response-related regimens should be applied to these patients in an effort to decrease SMNs.
| Original language | English |
|---|---|
| Title of host publication | Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy |
| Publisher | Elsevier Inc. |
| Pages | 61-74 |
| Number of pages | 14 |
| ISBN (Print) | 9780128008966 |
| DOIs | |
| Publication status | Published - Apr 2014 |
Fingerprint
Keywords
- Children
- Genetic aberrations
- Neuroblastoma
- Second malignancy
- Survival
- Treatment
ASJC Scopus subject areas
- Neuroscience(all)
Cite this
Second Malignancies in Children Following Treatment for Neuroblastoma. / Garaventa, Alberto; De Bernardi, Bruno.
Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy. Elsevier Inc., 2014. p. 61-74.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Second Malignancies in Children Following Treatment for Neuroblastoma
AU - Garaventa, Alberto
AU - De Bernardi, Bruno
PY - 2014/4
Y1 - 2014/4
N2 - On the basis of currently available information, the cumulative incidence of second malignant neoplasm (SMN) for neuroblastoma patients is approximately 2% at 20 years from the initial diagnosis. The most commonly observed SMNs include thyroid carcinomas, osteogenic and soft tissue sarcomas, breast and colon carcinomas, acute myeloid and lymphoid leukemias, Hodgkin's and non-Hodgkin's lymphomas, and brain tumors. Female survivors of neuroblastoma seem to be at higher risk of developing an SMN than males. Other predisposing factors include young age at the time of diagnosis of the first cancer, radiotherapy associated with chemotherapy, high-doses of alkylating agents and administration of topo-isomerase II inhibitors, as well as high cumulative doses and protracted schedules of epipodophyllotoxins. Longer and more targeted surveillance should be recommended including specific cancer screening at younger ages compared to the general population. Risk adapted and response-related regimens should be applied to these patients in an effort to decrease SMNs.
AB - On the basis of currently available information, the cumulative incidence of second malignant neoplasm (SMN) for neuroblastoma patients is approximately 2% at 20 years from the initial diagnosis. The most commonly observed SMNs include thyroid carcinomas, osteogenic and soft tissue sarcomas, breast and colon carcinomas, acute myeloid and lymphoid leukemias, Hodgkin's and non-Hodgkin's lymphomas, and brain tumors. Female survivors of neuroblastoma seem to be at higher risk of developing an SMN than males. Other predisposing factors include young age at the time of diagnosis of the first cancer, radiotherapy associated with chemotherapy, high-doses of alkylating agents and administration of topo-isomerase II inhibitors, as well as high cumulative doses and protracted schedules of epipodophyllotoxins. Longer and more targeted surveillance should be recommended including specific cancer screening at younger ages compared to the general population. Risk adapted and response-related regimens should be applied to these patients in an effort to decrease SMNs.
KW - Children
KW - Genetic aberrations
KW - Neuroblastoma
KW - Second malignancy
KW - Survival
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84902403450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902403450&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-800896-6.00006-1
DO - 10.1016/B978-0-12-800896-6.00006-1
M3 - Chapter
SN - 9780128008966
SP - 61
EP - 74
BT - Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy
PB - Elsevier Inc.
ER -